This article reviews the impact of obesity on hormonal contraceptives and hormone replacement therapy (HRT) at the climacteric, with emphasis on efficacy and adverse effects in relation to arterial and venous thrombosis, myocardial infarction and stroke. The association, whether causal or otherwise, between obesity, weight gain, hormonal contraception and HRT is discussed.
Introduction
Obesity is a major public health concern in the western world. In England and Wales, more than two-thirds of women and half of men are overweight (over 25 kg/m 2 ) or obese (over 30 kg/ m 2 ) according to standard definitions of body mass index (BMI). Does higher body weight affect the efficacy of hormonal contraceptives?
It has been suggested that higher body weight could enhance the metabolism of oral contraceptives and result in insufficient serum levels with suboptimal contraceptive efficacy, but does the available evidence support this claim?
In an uncontrolled study, Sparrow 1 found no increase in contraceptive failure in overweight women taking oral contraceptives. A cohort study by Vessey 2 of 17 032 women taking combined oral contraceptives and progestogen-only pills did not show statistical evidence of increased risk of accidental pregnancy in obese women. This study controlled for age and parity, but may have been insufficiently powered to confirm a suggested increase in the risk of accidental pregnancy. A retrospective cohort analysis 3 demonstrated a significantly elevated risk of failure (relative risk [RR] 1.6, 95% CI 1.1-2.4) in women with a body weight over 70.5 kg compared with women of a lower weight. In women weighing over 90 kg taking under 35 mg ethinylestradiol pills, the relative risk was 4.5 compared with a relative risk of 2.6 in users taking more than 50 mg ethinylestradiol pills. This study controlled for parity, race, religion and menstrual cycle, but was retrospective and did not take into account pill compliance, which may have contributed to pill failure. In another small study 4 of users of 20 mg combined oral contraceptives, women with a BMI over 25 showed reduced ovarian follicle suppression (RR 1.6, 95% CI 1-2.7) with a sevenday pill-free interval compared with women of normal weight; however, the study did not investigate failure rates due to inadequate ovarian suppression. A prospective case control study 5 showed that in consistent pill users with a BMI over 32, the risk of pregnancy was doubled i.e. an additional 2-4 pregnancies/100 woman-years of oral contraceptive use in overweight women. However, this caution is not justified, as the serum estradiol levels in the third year in overweight women are still well above threshold levels for ovulation suppression. There is a paucity of data on efficacy of etonogestrel implants in overweight women ( Table 1) .
Is there a causal relationship between hormonal contraception and weight gain?
For women choosing hormonal contraceptive methods, fear of weight gain is a real issue. Pill compliance can be dependent on the level of concern women have about perceived or actual weight gain. Rosenberg et al. 11 showed that the relative risk of discontinuing a pill due to weight gain was 1.4. Combined oral contraceptive associated weight gain can be related to stimulation of the renin-angiotensin mechanism by estrogens and fluid retention. 12 Estrogens can also be associated with increased subcutaneous fat, particularly in the breasts, hips and thighs. Progestogens are likely to increase appetite due to anabolic properties.
Gallo et al. 13 found no large effect on weight from three randomised, placebo-controlled trials. However, failure to report on allocation concealment, early discontinuations, loss to follow-up, or exclusion from trials after randomisation raises the question of bias. Clinical evidence does not support a causal association between combination skin patches and weight gain, but studies are required to address this question. No clinically demonstrable increase in body weight was noted in the combined contraceptive vaginal ring (norethindrone and ethinylestradiol) users. 14 The study failed to report on loss to follow-up, blinding, allocation concealment and randomisation. There is no indication to weigh women when prescribing combination contraceptives; however, in clinical practice, weighing women for opportunistic advice and reassurance is likely to be helpful. Perceived weight gain is a frequently reported adverse effect in implant users and a gradual mean increase in body weight over time amounting to 1.5-2% per year is observed with Norplant and Implanon contraceptive implant systems. 17 About 60% of women gain 1 kg by two years and 37% gain 3 kg. In a retrospective study 18 of young women using implants, an increase in BMI of 1.3 (P50.03) was noted and 42% of implants were removed due to weight gain. It has been suggested that women using a levonorgestrel intrauterine system may experience weight gain; however, clinical evidence does not support these claims. In a randomised study, 19 weight gain among levonorgestrel intrauterine system users and copper intrauterine device users was similar (0.49 kg/year); however, users of a levonorgestrel intrauterine system are more likely to cite weight gain as their reason for discontinuation. 
Bleeding irregularities
Bleeding patterns in progestogen-only pill users are not known to be affected by BMI. The slow decline in blood levels of progestogen in obese Depo-Provera users has not been directly linked to bleeding problems. However, a retrospective study of Depo-Provera users showed a lower incidence of bleeding problems in overweight women with a BMI over 30 (6%), compared with women with a BMI under 25 (13%). 20 High BMI also appears to offer protection against Depo-Provera related bone mineral density loss over two years.
Venous thromboembolism
Obesity is an independent risk factor for venous thromboembolism. The association between combined oral contraceptives and venous thromboembolism has been known since the 1960s, but the absolute risk attributable to combined oral contraceptive usage is small (15-25/100 000 users). 21 The pooled relative risk of venous thromboembolism for combined oral contraceptives containing desogestrel and gestodene versus levonorgestrel in a recent metaanalysis 22 was 1.7; a differential increase could not be explained by potential bias. Interim data from a large non-interventional comparative cohort study 23 of different combined oral contraceptives indicates a four-fold risk of venous thromboembolism in combined oral contraceptive users compared with non users. There was no significant difference between different progestogen formulations, including Yasmin, and this may be explained by the fact that women with predisposing risk factors for venous thromboembolism were not excluded. In a case controlled study 24 from The Netherlands, a BMI more than 30 doubled the risk of venous thromboembolism (adjusted for age and coagulation factor levels) compared with non users of normal weight. In a Danish study 25 of combined oral contraceptive users with BMIs of 26-30 and more than 31, the adjusted odds ratio of venous thromboembolism was 1.9 (95% CI51.5-2.5; P,0.01) and 5.1 (95% CI53.8-6.9; P,0.001), respectively ( 
Arterial disease
Obesity is an independent risk factor for arterial disease and is associated with worsening of the cardiovascular disease risk profile. Healthy young women with no known pre-existing risk factors (i.e. diabetes, hypertension, obesity) are at little, if any, risk of myocardial infarction from combined oral contraceptives. A statistically significant benefit in terms of reduced risk of myocardial infarction is associated with the use of desogestrel and gestodene combined oral contraceptives, but this was not studied in relation to obesity. 28 The odds ratio for myocardial infarction was 2 for the use of any combined oral contraceptive, 2.5 for levonorgestrel pill users and 1.3 for desogestrel and gestodene users; only five controls and two combined oral contraceptive users in this study had a BMI over 27.3.
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The WHO multicentre studies 21 of oral contraceptives and ischaemic stroke observed a pooled odds ratio in combined oral contraceptive users of 0.66 compared with 0.95 in those who had never used the pill. In Petitti et al. 30 crude odds ratios for ischaemic stroke were elevated in women with a high BMI (RR 4.9; 95% CI 2.6-9.1) compared with women of normal weight. The WHO multicentre observational studies suggest a small increase in risk of subarachnoid haemorrhage attributable to combined oral contraceptive use, but obesity per se with usage of combined oral contraceptives does not increase the risk further. More studies are required to clarify the risk of stroke among combined oral contraceptive users.
Study BMI Increase in risk of VTE 
HRT and breakthrough bleeding
A non-significant trend (P50.14) towards a relation between BMI and breakthrough bleeding became evident in one study 33 investigating the association of breakthrough bleeding in obese postmenopausal combined HRT users.
HRT and cardiovascular disease
Obesity is a risk factor for cardiovascular disease. HRT results in a three-fold increase in risk. In obese women, the adjusted odds ratio for venous thromboembolism is 4.6. Cushman et al. 32 found that the overall risk of venous thromboembolism was 3.5/100 woman-years in the HRT group compared with 1.7 in the placebo group. Concomitant progestin use is associated with an increased risk of venous thromboembolism compared with estrogen alone and esterified estrogens appear to be better in terms of risk compared with conjugated estrogens. 12 The risk of stroke in estrogen and estrogen-progestogen users was increased by 39% (8/10 000 more strokes/year) compared with women taking a placebo.
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Obesity is directly associated with an increased risk of polycystic ovarian syndrome, problems with induction of ovulation, lower birth rate after in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), endometrial cancer and postmenopausal breast cancer. Management of obesity should be recognised as an important component of gynaecological practice. Dietary modification, the help of a nutritionist and a suitable exercise programme are central to the management of obesity.
Conclusion
Future research should focus on the impact of BMI on the efficacy of contraceptive hormones and the impact of obesity on risks associated with female hormones. More understanding is required of mechanisms of bleeding patterns in progestogen users and the association of BMI and hormonal contraceptives with bleeding patterns.
